Hypomethylating therapy may activate, upregulate oncogene

Treatment with a hypomethylating agent may activate or upregulate SALL4, an oncogene that plays a key role in myelodysplastic syndrome and other cancers, according to study results published in The New England Journal of Medicine.
“Upregulation of SALL4 probably influences the clinical progression of the disease; similar biologic effects may accompany treatment with a hypomethylating agent in patients with cancers other than myelodysplastic syndrome,” Yao-Chung Liu, MD, of the department of pathology at Brigham and Women’s Hospital and division of hematology in the department

Treatment with a hypomethylating agent may activate or upregulate SALL4, an oncogene that plays a key role in myelodysplastic syndrome and other cancers, according to study results published in The New England Journal of Medicine.
“Upregulation of SALL4 probably influences the clinical progression of the disease; similar biologic effects may accompany treatment with a hypomethylating agent in patients with cancers other than myelodysplastic syndrome,” Yao-Chung Liu, MD, of the department of pathology at Brigham and Women’s Hospital and division of hematology in the department